Anaphylaxis

A survey reported that among 98.3% of respondents prescribed an epinephrine autoinjector for food allergies, 75.1% expressed concern about obtaining it.

In a recent study, a diagnostic protocol of 1:10 intradermal tests and subcutaneous provocation showed high accuracy for diagnosing immediate-type anesthetic allergy in children.

In children with septic shock, norepinephrine as the first vasoactive agent was linked to lower 30-day mortality than epinephrine, with no renal outcome difference.

Aquestive’s Anaphylm study showed positive pharmacokinetic results in children and adolescents, supporting its FDA submission.

A study found omalizumab enables faster, safer desensitization in children with food allergies, improving oral immunotherapy outcomes and reducing reactions.

A phase 1 study found neffy nasal spray provides effective epinephrine absorption in children, supporting its role as a needle-free anaphylaxis treatment.

Despite low food allergy prevalence in adults (0.31%), anaphylaxis remains common, highlighting the need for better diagnosis and emergency treatment.

A study found many anaphylaxis patients didn’t receive adrenaline, the first-line treatment. Adrenaline use correlated with better outcomes in adults and children.

New study highlights discrepancies in anaphylaxis severity scoring, emphasizing the need for a unified classification to improve treatment.

A study found ceftriaxone was the most common drug to lead to anaphylaxis in children.

A new study highlights key risk factors of cold-induced anaphylaxis, including genetic markers and elevated IgE, expanding on findings from the COLD-CE study.

Among 162 patients in the study, 99% reported satisfaction of sublingual immunotherapy with real grocery store food.

In this video, part 3 of a 5-part series, panelists discuss on how needle-free epinephrine and evolving therapies are reshaping food allergy management.

In this video, part 1 of a 5-part series, panelists discuss on recent advancements in pediatric food allergy and anaphylaxis management.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

The FDA approval for epinephrine nasal spray 1 mg is indicated for type 1 allergic reactions in children 15 to 30 kg and 4 years or older.

Castells discusses improvements in symptoms and quality of life scores for patients with indolent systemic mastocytosis across >2 years of the PIONEER trial.

A study at AAAAI 2025 found that monitoring transepidermal water loss during oral food challenges reduced anaphylaxis rates and epinephrine use in children.

A 46-member expert panel created a consensus anaphylaxis definition, overview, and clinical tool to aid clinicians in recognition and management across settings.

In this quiz, we test your knowledge of anaphylaxis risk assessment, prevention strategies, and best practices for enhancing preparedness.

A Kingston study finds a 15.94% biphasic anaphylaxis rate, with recurrence at 19 hours, prompting concerns about extending emergency department observation.

A study found higher daily temperatures increased anaphylaxis risk, except for cases related to medical procedures, highlighting heat's role in allergic reactions.

In this quiz, we test your knowledge of evidence-based management strategies, recommended epinephrine doses, and evolving guidance on patient follow-up and discharge planning for anaphylaxis.

A study found 1 in 7 children with anaphylaxis experience biphasic reactions after epinephrine, with no recurrences after 4 hours, highlighting corticosteroid impact.